Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Follow-Up Questions
Talphera Inc 'in CEO'su kimdir?
Mr. Vincent Angotti 2017 'den beri şirketle birlikte olan Talphera Inc 'in Chief Executive Officer 'ıdır.
TLPH hissesinin fiyat performansı nasıl?
TLPH 'in mevcut fiyatı $0.8822 'dir, son işlem günde 3.78% increased etti.
Talphera Inc için ana iş temaları veya sektörler nelerdir?
Talphera Inc Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Talphera Inc 'in piyasa değerlemesi nedir?
Talphera Inc 'in mevcut piyasa değerlemesi $40.1M 'dir
Talphera Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 5 analist Talphera Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 6 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
